Leveraging AI To Combat Cervical Cancer
IRP Researcher Identifies Precise Disease Biomarkers
Over the last few decades, advances in cervical cancer screening and prevention have fundamentally changed the approach to dealing with one of the most common forms of cancer in younger women. While doctors have been able to detect cancerous and pre-cancerous cells with a Pap smear since the 1940s, the more recent discovery that the human papillomavirus (HPV) causes more than 90 percent of cervical cancers now affords greater accuracy to regular screening tests. What’s more, IRP researchers truly changed the game by developing a vaccine against HPV, which was approved by the U.S. Food and Drug Administration (FDA) in 2006.
Still, despite these extremely positive developments, much work remains to be done, as cervical cancer continues to kill about 4,000 American women each year. In honor of World Cervical Cancer Awareness Month this January, we spoke with IRP Senior Investigator Nicolas Wentzensen, M.D., Ph.D., about his efforts to bring that number as close to zero as possible.